In this retrospective cohort study of electronic health records (EHRs) from the TriNetX Analytics Network, a global federated health research network of approximately 105.3 million patients from 61 large healthcare organizations in the US, we aimed to assess the associations of semaglutide with both incident and recurrent CUD diagnosis compared to non-GLP-1RA anti-obesity or anti-diabetes medications
Research-Based Cycle Protocols Short-Term Assessment (4-8 Weeks): An initial 4-8 week cycle allows evaluation of individual response, tolerance assessment, and metabolic changes without extended commitment
Oxidative throughput can approach or exceed regenerative capacity without requiring overt depletion of metabolites
"What we're seeing is a greater potential for adverse events, which makes sense because we're now treating three different pathways and patients are experiencing far more weight loss," McGowan said
Optimizing Your Health on GLP-1 Therapy Taking a GLP-1 medication involves more than just an injection or a pill
At this time there is no conclusive evidence that GLP-1 medications directly damage the microbiome, but changes in appetite, meal size, and food variety can influence microbial diversity over time